BEXIMCO PHARMA.GDR REGS 1 (R2WA) — Cash Flow Reinvestment Rate
BEXIMCO PHARMA.GDR REGS 1 (R2WA) has a Cash Flow Reinvestment Rate of 0.29x as of June 2024, reinvesting €2.43 Billion (capex €2.23 Billion plus investments €-200.00 Million) from operating cash flow of €8.36 Billion. Check BEXIMCO PHARMA.GDR REGS 1 (R2WA) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
BEXIMCO PHARMA.GDR REGS 1 Cash Flow Reinvestment Rate (2022–2024)
Historical reinvestment intensity for BEXIMCO PHARMA.GDR REGS 1 across 3 annual periods. Explore R2WA debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for BEXIMCO PHARMA.GDR REGS 1 (2022–2024)
Year-by-year capital reinvestment analysis for BEXIMCO PHARMA.GDR REGS 1. For live market cap and broader valuation context, see R2WA stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.29x | €2.43 Billion | €8.36 Billion | €2.23 Billion | ▼ -34.6% |
| 2023 | 0.45x | €2.71 Billion | €6.08 Billion | €2.71 Billion | ▼ -21.0% |
| 2022 | 0.56x | €2.94 Billion | €5.21 Billion | €2.94 Billion | — |